Inamed, Genzyme Win OK for Wrinkle Gel
From Bloomberg News
Inamed Corp. and its partner Genzyme Corp. won Food and Drug Administration approval of the Hylaform gel to treat wrinkles around the eyes and mouth.
Inamed, which already sells other wrinkle fillers, will compete with Medicis Pharmaceutical Corp.’s Restylane, which won U.S. approval in December.
Shares of Santa Barbara-based Inamed rose $2 to $55.50 on Nasdaq. Genzyme shares fell 64 cents to $46.46, also on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
